Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2025
Business Overview: BD is a global medical technology company developing, manufacturing, and selling medical supplies, devices, laboratory equipment, and diagnostic products. As of September 30, 2025, operations were organized into three segments: BD Medical, BD Life Sciences, and BD Interventional. Effective October 1, 2025, the company reorganized into five segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences.
Key Financial Metrics
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenues | $21.840 billion | $20.178 billion | $19.372 billion |
| Operating Income | $2.579 billion | $2.397 billion | $2.111 billion |
| Net Income (Continuing Ops) | $1.678 billion | $1.705 billion | $1.530 billion |
| Diluted EPS (Continuing Ops) | $5.82 | $5.86 | $5.10 |
| Gross Profit Margin | 45.4% | 45.2% | 42.2% |
| Operating Cash Flow | $3.430 billion | $3.844 billion | $2.990 billion |
| Total Debt | $19.181 billion | $20.110 billion | $15.879 billion |
| Cash & Equivalents | $859 million | $1.856 billion | $1.481 billion |
Material Changes vs. Prior Period
- Revenue Growth: Worldwide revenues increased 8.2% to $21.840 billion. Growth was driven by a 4.8% impact from the acquisition of Advanced Patient Monitoring, 3.2% volume/other growth, and 0.1% foreign currency impact, partially offset by a 0.3% pricing decrease.
- Segment Performance:
- Medical: Revenues grew 13.7% to $11.456 billion, driven by the Advanced Patient Monitoring acquisition and growth in Medication Delivery and Management Solutions.
- Life Sciences: Revenues declined 0.5% to $5.167 billion due to lower sales in Diagnostic Solutions and Biosciences, partially offset by growth in Specimen Management.
- Interventional: Revenues grew 4.8% to $5.217 billion, driven by strong performance in Surgery, Peripheral Intervention, and Urology/Critical Care.
- Profitability: Operating income increased to $2.579 billion. Gross margin expanded to 45.4% due to lower manufacturing costs and favorable product mix, partially offset by tariffs and higher labor costs.
- Acquisitions & Divestitures:
- Completed acquisition of Edwards Lifesciences' Critical Care product group (Advanced Patient Monitoring) for $3.914 billion in September 2024.
- Entered a definitive agreement in July 2025 to combine its Biosciences and Diagnostic Solutions business with Waters Corporation (expected to close Q1 2026).
Guidance, Outlook, Risks, and Unusual Items
- Outlook & Strategy: BD remains focused on "Grow, Simplify, and Empower" strategic pillars. The company expects tariffs to adversely impact operating expenses in fiscal year 2026. The proposed combination with Waters is expected to generate approximately $4 billion in cash distribution to BD prior to completion.
- Regulatory Risks:
- FDA Consent Decree: The U.S. infusion pump business operates under a Consent Decree. BD received a Warning Letter in November 2024 regarding its Dispensing quality management system and recorded a $98 million liability for remediation costs. Remediation of Alaris infusion systems is ongoing.
- Ethylene Oxide (EtO): Increased EPA regulation on EtO emissions may require facility upgrades and operational changes, potentially impacting sterilization capacity and costs.
- Legal Contingencies: BD is defending approximately 6,905 hernia repair device claims and 2,380 implantable port claims. Accruals for product liability and legal matters totaled approximately $1.8 billion as of September 30, 2025. A $175 million payment was made to the SEC in Q1 2025 to resolve an investigation.
- Unusual Items: Specified items impacting 2025 results included $1.898 billion in purchase accounting adjustments (primarily related to Advanced Patient Monitoring), $275 million in restructuring costs, and $548 million in product, litigation, and other items.
Investor Verification Checklist
- Waters Transaction Status: Verify the progress of regulatory approvals and the expected closing timeline for the Biosciences/Diagnostic Solutions combination with Waters Corporation.
- FDA Compliance Costs: Monitor the final cost and operational impact of resolving the FDA Warning Letter regarding the Dispensing quality management system and the ongoing Consent Decree requirements for infusion pumps.
- Tariff Impact: Assess the actual impact of new tariffs on operating expenses and supply chain costs in fiscal year 2026 as projected by management.
- Legal Accruals: Review updates on the $1.8 billion accrual for product liability claims, specifically regarding hernia repair devices and implantable ports, to ensure reserves remain adequate.
- Segment Reorganization: Confirm the financial reporting impact of the transition from three to five business segments effective October 1, 2025.